Speculation surrounding a potential sale of EBOS Group, the $3.4 billion Australian pharmacy and pet care company, continues to circulate amid heightened interest from private equity buyers. Market sources indicate that investment bankers remain active in promoting the business to prospective suitors, keeping EBOS among the most discussed targets in private equity circles.
TPG Capital has emerged in conversations as a possible bidder, although the firm has publicly denied any plans to pursue EBOS. The mention of TPG is notable given the firms’ previous dealings and established relationship. Last week, reports highlighted that TPG had raised its full-year fundraising target to a record $55 billion, resulting in $86 billion of uncommitted capital available for investment. EBOS was linked with Greencross, a pet care business owned by TPG, when it nearly acquired Greencross for $4 billion in 2023 before withdrawing at the last minute. EBOS and Greencross also co-own the pet retailer Animates in New Zealand.
Industry participants point to ongoing deal-making efforts as an indication that a full or partial sale of EBOS may be forthcoming. The company’s chief executive, Adam Hall, declined to comment on potential sale plans when approached for comment.
EBOS operates primarily in wholesale pharmacy supply, which remains its core business. However, the company’s performance has been constrained since it lost a major contract with Chemist Warehouse in 2024. That $1.1 billion annual contract was awarded to Sigma, following a merger involving Chemist Warehouse and Sigma. The contract had accounted for roughly 17 percent of EBOS’s annual revenue, and its loss has weighed heavily on the company’s financial results.
In the aftermath, EBOS has been actively seeking acquisition opportunities. It is the largest marketer, wholesaler, and distributor of healthcare and pharmaceutical products across Australia and New Zealand, controlling about half of the Australian community wholesale pharmacy market. The company also operates the Terry White Chemmart pharmacy chain, which includes around 600 stores in both countries.
Despite these strengths, EBOS’s shares have declined approximately 30 percent over the past year, reflecting investor concerns. Recent reports have highlighted significant executive departures from the company, a development some analysts find noteworthy amid mounting market pressure and the possibility of a sale. EBOS also generates about 10 percent of its earnings from Black Hawk Pet Food, a brand it owns.
Australia comprises about 65 percent of EBOS’s overall business, underscoring the company’s dominant position in the region’s healthcare and pet care sectors. As private equity interest persists, the strategic direction of EBOS remains closely watched by market participants.